ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.

Hiroto Inaba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.